Chronic Hepatitis B Market Chronic Hepatitis B is a diverse condition characterized by widely varying degrees of viral replication and liver disease...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - MOUNTAINTODAY.IN - A La Une - 11/Jul 18:36
Hepatitis B Virus Infection Pipeline 2024 | Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences
DelveInsight, “Hepatitis B Virus Infection Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Hepatitis B Virus Infection pipeline landscape. It covers the Hepatitis
Articles similaires
Interstitial Cystitis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest EMA, PDMA, FDA Approvals by DelveInsight | Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics
mountaintoday.in - 04/Sep 07:57
Interstitial Cystitis market The Interstitial Cystitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)....
Interstitial Cystitis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest EMA, PDMA, FDA Approvals by DelveInsight | Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics
mountaintoday.in - 04/Sep 07:57
Interstitial Cystitis market The Interstitial Cystitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)....
VIR COMBINATION (adenoviren nosode, cytomegalovirus nosode, herpes simplex virus 1 dna, herpes simplex virus 2 dna, epstein-barr virus nosode, hepatitis b nosode, herpes simplex 1 nosode, herpes simplex 2 nosode, human herpesvirus 6a, human herpesvirus 6b, influenzinum (2023-2024)) liquid [Deseret Biologicals, Inc.]
nlm.nih.gov - 29/Aug 04:00
Updated Date: Thu, 29 Aug 2024 00:00:00 EDT
VIR COMBINATION (adenoviren nosode, cytomegalovirus nosode, herpes simplex virus 1 dna, herpes simplex virus 2 dna, epstein-barr virus nosode, hepatitis b nosode, herpes simplex 1 nosode, herpes simplex 2 nosode, human herpesvirus 6a, human herpesvirus 6b, influenzinum (2022-2023)) liquid [Deseret Biologicals, Inc.]
nlm.nih.gov - 29/Aug 04:00
Updated Date: Thu, 29 Aug 2024 00:00:00 EDT
Syneos Health: Research Nurse-Bordeaux, France
pharmiweb.com - 09/Sep 00:00
Competitive: Syneos Health: Research Nurse Illingworth Research Group provides a range of patient focused clinical services to the pharmaceutical,...
Syneos Health: Research Nurse-Marseilles, France
pharmiweb.com - 09/Sep 00:00
Competitive: Syneos Health: Research Nurse Illingworth Research Group provides a range of patient focused clinical services to the pharmaceutical,...
Twice-Yearly Injection Cuts HIV Risk by 96%, But Will Cost Cut Access?
drugs.com - 16:09
THURSDAY, Sept. 12, 2024 -- It could be a real breakthrough for people at risk for HIV infection: A shot given every six months that reduces their...
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?
zacks.com - 09/Sep 13:40
Here is how HCA Healthcare (HCA) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Interstitial Cystitis Market Growth Anticipated by 2032 | Companies includes Merck, Teva Pharmaceutical, Lipella Pharmaceuticals, Seikagaku Corporation
mountaintoday.in - 09:16
Interstitial Cystitis Market The therapeutic landscape for Interstitial Cystitis in the United States is shaped by existing treatment practices and...
Les derniers communiqués
-
Aucun élément